Indications
Long-term prophylactic treatment of bleeding in adult and paediatric patients 6 years and above with congenital factor-XIII-A-subunit deficiency.
Composition
- Active substance
- catridecacog
Official product information
The European public assessment report holds the summary of product characteristics and the package leaflet in every EU language.
Prognia shows this product information for reference and learning. It is not treatment advice and can lag behind the official text. Always check the current product information and local protocols before prescribing.
At a glance
- Medicine
- NovoThirteen
- Active substance
- catridecacog
- ATC code
- B02BD11
- Therapeutic area
- Blood Coagulation Disorders, Inherited
- Marketing authorisation holder
- Novo Nordisk A/S
- Status
- Authorised
- EU authorisation
- 3 Sept 2012